CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

CureVac ( (CVAC) ) has issued an update. CureVac N.V. released its unaudited interim condensed consolidated financial statements for the period ending June 30, 2025, revealing a substantial decline ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

New members to the Access Advance patent pool and Harvard University coming under fire were also among the top talking points ...